FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martin Tallman

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Martin S Tallman; George B McDonald; Maria R Baer; Michael N Cook; Laurie D DeLeve; G Jay Graepel; Carl Kollmer
Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice.
Gannie Tzoneva; Maddalena Allegretta; Giuseppe Basso; Zachary Carpenter; Jana Hof; Hossein Khiabanian; Renate Kirschner-Schwabe; Maddalena Paganin; Elisabeth Paietta; Teresa Palomero; Arianne Perez-Garcia; Raul Rabadan; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Valeria Tosello; Adolfo Ferrando
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Eytan M Stein; Martin S Tallman
Persistent problems with persistent disease: minimal residual disease in acute myelogeous leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martin Tallman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Martin S Tallman; George B McDonald; Maria R Baer; Michael N Cook; Laurie D DeLeve; G Jay Graepel; Carl Kollmer
Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice.
International journal of hematology 2013;97(4):456-64.
2013: Gannie Tzoneva; Maddalena Allegretta; Giuseppe Basso; Zachary Carpenter; Jana Hof; Hossein Khiabanian; Renate Kirschner-Schwabe; Maddalena Paganin; Elisabeth Paietta; Teresa Palomero; Arianne Perez-Garcia; Raul Rabadan; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Valeria Tosello; Adolfo Ferrando
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Nature medicine 2013;19(3):368-71.
2013: Eytan M Stein; Martin S Tallman
Persistent problems with persistent disease: minimal residual disease in acute myelogeous leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013;19(2):170-1.
2013: Adi Diab; Dan Douer; Hugo F Fernandez; Manjit A Gulam; Suresh Jhanwar; Joseph G Jurcic; Hillard M Lazarus; Ross L Levine; Mark R Litzow; Selina M Luger; James K Mangan; Peter Maslak; Elisabeth Paietta; Katherine S Panageas; Jay P Patel; Jacob M Rowe; Omar Abdel-Wahab; Martin Carroll; Julie Teruya-Feldstein; Lynette Zickl; Martin S Tallman
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis.
Leukemia research 2013;37(1):32-6.
2012: David Cella; Du Hongyan; Sally E Jensen; Jin-Shei Lai; Steven Rosen; Martin S Tallman; Kimberly Webster; Susan Yount
Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy--Leukemia (FACT-Leu) questionnaire.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2012;15(8):1051-8.
2012: Huimin Geng; Monica L Guzman; Chuanxin Huang; Christian Hurtz; Rhett P Ketterling; Soo-Mi Kweon; Hillard Lazarus; Yushan Li; Mark R Litzow; Selina M Luger; Thomas A Milne; Markus Müschen; Donna Neuberg; Elisabeth Paietta; Janis Racevskis; Robert G Roeder; Jacob M Rowe; Seyedmehdi Shojaee; Martin S Tallman; Yuan Xin; Lynette Zickl; C David Allis; Debabrata Biswas; Sarah Brennan; Wei-Yi Chen; Olivier Elemento; Ari M Melnick
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
Cancer discovery 2012;2(11):1004-23.
2012: Eytan M Stein; Martin S Tallman
Does arsenic trioxide impact fertility?
Leukemia & lymphoma 2012;53(11):2099-100.
2012: Mithat Gonen; Rhett P Ketterling; Ross L Levine; Ari Melnick; Jay P Patel; Janis Racevskis; Jacob M Rowe; Zhuoxin Sun; Martin S Tallman; Omar Abdel-Wahab; Hugo Fernandez; Maria E Figueroa; Elisabeth Paietta
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.
Blood 2012;120(11):2297-306.
2012: Robert E Gallagher; Richard Harvey; Rhett P Ketterling; Greg Koval; Richard A Larson; Barry K Moser; Elisabeth Paietta; Xavier Poiré; Bayard L Powell; Janis Racevskis; Diane Roulston; Esther Schachter-Tokarz; Dorie A Sher; Frederick R Appelbaum; Clara D Bloomfield; Andrew J Carroll; I-Ming L Chen; James H Feusner; Martin S Tallman; Cheryl L Willman; Da-Cheng Zhou; Wendy Stock
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
Blood 2012;120(10):2098-108.
2012: Tsila Zuckerman; Martin S Tallman; Chezi Ganzel; Jacob M Rowe
How I treat hematologic emergencies in adults with acute leukemia.
Blood 2012;120(10):1993-2002.
2012: Peter H Wiernik; Frederick R Appelbaum; Peter A Cassileth; Gordon Dewald; Holly Gundacker; Haesook T Kim; Elisabeth Paietta; Marilyn L Slovak; Zhuoxin Sun; Martin S Tallman
Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).
Medical oncology (Northwood, London, England) 2012;29(3):2095-101.
2012: Eytan M Stein; Martin S Tallman
Remission induction in acute myeloid leukemia.
International journal of hematology 2012;96(2):164-70.
2012: Eytan M Stein; Martin S Tallman
Provocative pearls in diagnosing and treating acute promyelocytic leukemia.
Oncology (Williston Park, N.Y.) 2012;26(7):636-41.
2012: E M Stein; Martin S Tallman
Novel and emerging drugs for acute myeloid leukemia.
Current cancer drug targets 2012;12(5):522-30.
2012: Robert J Kreitman; Robert Lechleider; Steven Coutre; David J Fitzgerald; Tadeusz Robak; Maryalice Stetler-Stevenson; Martin S Tallman; Wyndham H Wilson; Ira Pastan
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(15):1822-8.
2012: Martin S Tallman
Novel therapeutic strategies for AML in 2012.
Hematology (Amsterdam, Netherlands) 2012;17 Suppl 1():S43-6.
2012: Altuna Akalin; C David Allis; Debabrata Biswas; Jennifer Busuttil; Ruud Delwel; Hugo F Fernandez; Francine E Garrett-Bakelman; Jay L Hess; Yongsheng Huang; Irina Khrebtukova; Matthias Kormaksson; Bob Löwenberg; Christopher E Mason; Ari Melnick; Thomas A Milne; Elisabeth Paietta; Robert G Roeder; Gary P Schroth; Martin S Tallman; Peter J M Valk; Lu Zhang; Maria E Figueroa
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.
PLoS genetics 2012;8(6):e1002781.
2011: Sherif S Farag; Stephen L George; Luis Isola; Richard A Larson; Hillard M Lazarus; Mark R Litzow; Kati Maharry; Guido Marcucci; David I Marks; Krzysztof Mrózek; Waleska S Pérez; Olle Ringdén; David A Rizzieri; Robert Soiffer; Martin S Tallman; Daniel J Weisdorf; Mei-Jie Zhang; Maria R Baer; Clara D Bloomfield; Donald W Bunjes; Mitchell S Cairo; Edward Copelan; Corey Cutler; John DiPersio
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2011;17(12):1796-803.
2011: Jae Park; Todd Rosenblat; Joseph G Jurcic; Martin S Tallman
Emerging new approaches for the treatment of acute promyelocytic leukemia.
Therapeutic advances in hematology 2011;2(5):335-52.
2011: Aaron D Schimmer; Karen Seiter; Martin S Tallman; Sonja Martin; Richard Noppeney; Gautham Borthakur; Pierre Desjardins; Walter Fiedler; Arthur Frankel; Aristoteles Giagounidis; Mathias Hänel; Wolfgang Herr; Heinz-August Horst; Christine Jacob; Jacques Jolivet; Jeannine Kassis; Steffen Koschmieder
Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.
Clinical lymphoma, myeloma & leukemia 2011;11(5):433-8.
2011: Donald A Berry; Marco Bregni; Jean Caputo; R Charles Coombes; John P Crown; Elisabeth G E de Vries; William E Barlow; Russell L Basser; Jonas Bergh; ALESSANDRO MASSIMO GIANNI; Gabriel N Hortobagyi; Marcella M Johnson; Xiudong Lei; Robert C Leonard; Ulrike A Nitz; Paolo Pedrazzoli; William P Peters; Henri Roché; Sjoerd Rodenhuis; Martin S Tallman; Yutaka Tokuda; Naoto T Ueno; Axel R Zander; Taner Demirer
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(24):3214-23.
2011: Jae H Park; Baozhen Qiao; Todd L Rosenblat; Jacob M Rowe; Maria J Schymura; Jessica K Altman; Dan Douer; Joseph G Jurcic; Katherine S Panageas; Martin S Tallman
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.
Blood 2011;118(5):1248-54.
2011: F Pettersson; Martin S Tallman; H J Gronemeyer; J Licht; W H Miller; C Nervi; S Waxman
The 12th international conference on differentiation therapy: targeting the aberrant growth, differentiation and cell death programs of cancer cells.
Cell death and differentiation 2011;18(7):1231-3.
2011: Martin S Tallman
Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping.
Leukemia & lymphoma 2011;52 Suppl 2():65-8.
2011: Hugo F Fernandez; Zhuoxin Sun; Mark R Litzow; Selina M Luger; Elisabeth Paietta; Janis Racevskis; Gordon Dewald; Rhett P Ketterling; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.
Blood 2011;117(20):5306-13.
2011: Mark Levis; Farhad Ravandi; Eunice S Wang; Maria R Baer; Alexander Perl; Steven Coutre; Harry P Erba; Robert K Stuart; Michele Baccarani; Larry D Cripe; Martin S Tallman; Giovanna Meloni; Lucy A Godley; Amelia A Langston; Sergio Amadori; Ian D Lewis; Arnon Nagler; Richard Stone; Karen Yee; Anjali Advani; Dan Douer; W Wiktor-Jedrzejczak; Gunnar Juliusson; Mark R Litzow; Stephen Petersdorf; Miguel Sanz; Hagop M Kantarjian; Takashi X Sato; Lothar Tremmel; Debra M Bensen-Kennedy; Donald Small; B Douglas Smith
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
Blood 2011;117(12):3294-301.
2011: Jae H Park; Cyrus V Hedvat; Martin S Tallman
Blood consult: acute myeloid leukemia and the t(8;21)(q22;22).
Blood 2011;117(10):2775-7.
2011: Margaret R O'Donnell; Camille N Abboud; Jessica Altman; Frederick R Appelbaum; Steven E Coutre; Lloyd E Damon; James M Foran; Salil Goorha; Lori J Maness; Guido Marcucci; Peter Maslak; Michael M Millenson; Joseph O Moore; Farhad Ravandi; Paul J Shami; B Douglas Smith; Richard M Stone; Stephen A Strickland; Martin S Tallman; Eunice S Wang
Acute myeloid leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(3):280-317.
2011: Vikas Gupta; Martin S Tallman; Daniel J Weisdorf
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns.
Blood 2011;117(8):2307-18.
2011: Martin S Tallman; Gulam A Manji
Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
Blood cells, molecules & diseases 2011;46(2):173-4.
2011: Olga Frankfurt; Martin S Tallman
The hematopoietic growth factors in acute leukemia: U.S. perspective.
Cancer treatment and research 2011;157():307-37.
2011: P Van Vlierberghe; J Patel; O Abdel-Wahab; C Lobry; Cyrus V Hedvat; M Balbin; C Nicolas; A R Payer; H F Fernandez; Martin S Tallman; Elisabeth Paietta; A Melnick; P Vandenberghe; F Speleman; Ioannis Aifantis; J Cools; R Levine; Adolfo Ferrando
PHF6 mutations in adult acute myeloid leukemia.
Leukemia 2011;25(1):130-4.
2011: Virginia M Klimek; Martin S Tallman
Hypomethylating agents in acute lymphoblastic leukemia: untapped potential?
Leukemia & lymphoma 2011;52(1):7-8.
2011: David Grimwade; Martin S Tallman
Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?
Leukemia research 2011;35(1):3-7.
2010: Martin S Tallman; Haesook T Kim; Pau Montesinos; Frederick R Appelbaum; Javier de la Serna; John M Bennett; Guillermo Deben; Clara D Bloomfield; Jose Gonzalez; James H Feusner; Marcos Gonzalez; Robert E Gallagher; Jose D Gonzalez-San Miguel; Richard A Larson; Gustavo Milone; Elisabeth Paietta; Chelo Rayon; Jacob M Rowe; Concha Rivas; Charles Alan Schiffer; Edo Vellenga; Lois Shepherd; James L Slack; Peter H Wiernik; Cheryl L Willman; Miguel A Sanz
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
Blood 2010;116(25):5650-9.
2010: Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig Thompson; Ross L Levine; Ari Melnick
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Cancer cell 2010;18(6):553-67.
2010: Polina Khrizman; Jessica K Altman; Arash Mohtashamian; LoAnn Peterson; Yi-Hua Chen; Martin S Tallman
Charcot-Leyden crystals associated with acute myeloid leukemia: case report and literature review.
Leukemia research 2010;34(12):e336-8.
2010: Ruben A Mesa; Xiaopan Yao; Larry D Cripe; Chin-Yang Li; Mark R Litzow; Elisabeth Paietta; Jacob M Rowe; Ayalew Tefferi; Martin S Tallman
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
Blood 2010;116(22):4436-8.
2010: Larry D Cripe; Hajime Uno; Elisabeth Paietta; Mark R Litzow; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Selina Luger; Martin S Tallman
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.
Blood 2010;116(20):4077-85.
2010: Bayard L Powell; Barry Moser; Wendy Stock; Robert E Gallagher; Cheryl L Willman; Richard M Stone; Jacob M Rowe; Steven Coutre; James H Feusner; John Gregory; Stephen Couban; Frederick R Appelbaum; Martin S Tallman; Richard A Larson
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
Blood 2010;116(19):3751-7.
2010: Jacob M Rowe; Haesook T Kim; Peter A Cassileth; Hillard M Lazarus; Mark R Litzow; Peter H Wiernik; Martin S Tallman
Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.
Cancer 2010;116(21):5012-21.
2010: Jacob M Rowe; Martin S Tallman
How I treat acute myeloid leukemia.
Blood 2010;116(17):3147-56.
2010: Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.
Blood 2010;116(14):2420-8.
2010: Martin S Tallman; Dan Douer; Steven D Gore; Bayard L Powell; Farhad Ravandi; Jacob Rowe; Aarati Ranganathan; Miguel A Sanz
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.
Clinical lymphoma, myeloma & leukemia 2010;10 Suppl 3():S122-6.
2010: Ritesh Parajuli; Jessica Altman; Timothy Kuzel; Maria Perdekamp; Martin S Tallman
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
American journal of hematology 2010;85(10):829.
2010: Jessica K Altman; Heather Glaser; Antonella Sassano; Sonali Joshi; Takeshi Ueda; Rie Watanabe-Fukunaga; Rikiro Fukunaga; Martin S Tallman; Leonidas C Platanias
Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses.
Molecular pharmacology 2010;78(4):778-84.
2010: Dennis J Goussetis; Jessica K Altman; Heather Glaser; Jennifer L McNeer; Martin S Tallman; Leonidas C Platanias
Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.
The Journal of biological chemistry 2010;285(39):29989-97.
2010: Vikas Gupta; Martin S Tallman; Wensheng He; Brent R Logan; Edward Copelan; Robert Peter Gale; Hanna J Khoury; Thomas Klumpp; John Koreth; Hillard M Lazarus; David I Marks; Rodrigo Martino; David A Rizzieri; Jacob M Rowe; Mitchell Sabloff; Edmond WALLER; John F DiPersio; Donald W Bunjes; Daniel J Weisdorf
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.
Blood 2010;116(11):1839-48.
2010: Michel Duval; John P Klein; Wensheng He; Jean-Yves Cahn; Mitchell S Cairo; Bruce M Camitta; Rammurti Kamble; Edward A Copelan; Marcos de Lima; Vikas Gupta; Armand Keating; Hillard M Lazarus; Mark R Litzow; David I Marks; Richard T Maziarz; David A Rizzieri; Gary Schiller; Kirk R Schultz; Martin S Tallman; Daniel Weisdorf
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(23):3730-8.
2010: David I Marks; Tao Wang; Waleska S Pérez; Joseph H Antin; Edward A Copelan; Robert Peter Gale; Biju George; Vikas Gupta; Joerg Halter; H Jean Khoury; Thomas R Klumpp; Hillard M Lazarus; Victor A Lewis; Philip McCarthy; David A Rizzieri; Mitchell Sabloff; Jeff Szer; Martin S Tallman; Daniel J Weisdorf
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.
Blood 2010;116(3):366-74.
2010: Martin S Tallman
All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'.
Leukemia & lymphoma 2010;51(5):745-6.
2010: Brian L McClune; Daniel J Weisdorf; Tanya L Pedersen; Gisela Tunes da Silva; Martin S Tallman; Jorge Sierra; John DiPersio; Armand Keating; Robert P Gale; Biju George; Vikas Gupta; Theresa Hahn; Luis Isola; Madan Jagasia; Hillard Lazarus; David Marks; Richard T Maziarz; Edmond WALLER; Chris Bredeson; Sergio Giralt
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(11):1878-87.
2010: Roland B Walter; Hagop M Kantarjian; Xuelin Huang; Sherry A Pierce; Zhuoxin Sun; Holly M Gundacker; Farhad Ravandi; Stefan H Faderl; Martin S Tallman; Frederick R Appelbaum; Elihu H Estey
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(10):1766-71.
2010: Mark R Litzow; Sergey Tarima; Waleska S Pérez; Brian J Bolwell; Mitchell S Cairo; Bruce M Camitta; Corey S Cutler; Marcos de Lima; John F Dipersio; Robert Peter Gale; Armand Keating; Hillard M Lazarus; Selina Luger; David I Marks; Richard T Maziarz; Philip L McCarthy; Marcelo C Pasquini; Gordon L Phillips; J Douglas Rizzo; Jorge Sierra; Martin S Tallman; Daniel J Weisdorf
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.
Blood 2010;115(9):1850-7.
2010: Martin S Tallman
Updates on the treatment of acute promyelocytic leukemia.
Clinical advances in hematology & oncology : H&O 2010;8(2):89-90.
2010: Tamar Tadmor; Martin S Tallman; Aaron Polliack
Sorafenib - a small molecule with big promise?
Leukemia & lymphoma 2010;51(2):181-2.
2010: Roneil G Malkani; Martin S Tallman; Numa Gottardi-Littell; William J Karpus; Laura Marszalek; Daina Variakojis; Bruce Kaden; Matthew Walker; Robert M Levy; Jeffrey J Raizer
Bing-Neel syndrome: an illustrative case and a comprehensive review of the published literature.
Journal of neuro-oncology 2010;96(3):301-12.
2010: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo Coco; Tomoki Naoe; Dietger Niederwieser; Gert Ossenkoppele; MA Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Blood 2010;115(3):453-74.
2010: Priya P Gor; H Irene Su; Robert J Gray; Phyllis A Gimotty; Michelle Horn; Richard Aplenc; William P Vaughan; Martin S Tallman; Timothy R Rebbeck; Angela DeMichele
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
Breast cancer research : BCR 2010;12(3):R26.
2010: Mark R Litzow; Megan Othus; Larry D Cripe; Steven D Gore; Hillard M Lazarus; Sandra J Lee; John M Bennett; Elisabeth Paietta; Gordon W Dewald; Jacob M Rowe; Martin S Tallman
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
British journal of haematology 2010;148(2):217-25.
2009: David I Marks; Elisabeth Paietta; Anthony V Moorman; Susan M Richards; Georgina Buck; Gordon DeWald; Adolfo Ferrando; Adele K Fielding; Anthony H Goldstone; Rhett P Ketterling; Mark R Litzow; Selina M Luger; Andrew K McMillan; Marc R Mansour; Jacob M Rowe; Martin S Tallman; Hillard M Lazarus
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
Blood 2009;114(25):5136-45.
2009: Martin S Tallman; Jessica K Altman
How I treat acute promyelocytic leukemia.
Blood 2009;114(25):5126-35.
2009: John Gregory; Haesook Kim; Todd Alonzo; Rob Gerbing; William Woods; Howard Weinstein; Lois Shepherd; Charles Alan Schiffer; Frederick Appelbaum; Cheryl Willman; Peter Wiernik; Jacob Rowe; Martin S Tallman; James Feusner
Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129.
Pediatric blood & cancer 2009;53(6):1005-10.
2009: Francis Giles; Norbert Vey; Daniel J DeAngelo; Karen Seiter; Wendy Stock; Robert Stuart; Darinka Boskovic; Arnaud Pigneux; Martin S Tallman; Joseph Brandwein; Jonathan Kell; Tadeusz Robak; Peter Staib; Xavier Thomas; Ann Cahill; Maher Albitar; Susan O'Brien
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Blood 2009;114(19):4027-33.
2009: R Bhat; S Malinge; A S Gamis; A D Sorrell; J M Hilden; R P Ketterling; Elisabeth Paietta; Martin S Tallman; J D Crispino
Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia.
Leukemia 2009;23(11):2159-60.
2009: Maria E Figueroa; Lucy Skrabanek; Yushan Li; Anchalee Jiemjit; Tamer E Fandy; Elisabeth Paietta; Hugo Fernandez; Martin S Tallman; John M Greally; Hetty Carraway; Jonathan D Licht; Steven D Gore; Ari Melnick
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Blood 2009;114(16):3448-58.
2009: Susan O'Brien; Ellin Berman; Hossein Borghaei; Daniel J Deangelo; Marcel P Devetten; Steven Devine; Harry P Erba; Jason Gotlib; Madan Jagasia; Joseph O Moore; Tariq Mughal; Javier Pinilla-Ibarz; Jerald P Radich; Neil P Shah Md; Paul J Shami; B Douglas Smith; David S Snyder; Martin S Tallman; Moshe Talpaz; Meir Wetzler
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(9):984-1023.
2009: Martin S Tallman; Aaron Polliack
Historical aspects and milestones in the development of effective treatment for hairy cell leukemia.
Leukemia & lymphoma 2009;50 Suppl 1():2-7.
2009: Aaron D Schimmer; Elihu H Estey; Gautam Borthakur; Bing Z Carter; Gary J Schiller; Martin S Tallman; Jessica K Altman; Judith E Karp; Jeannine Kassis; David W Hedley; Joseph Brandwein; Wei Xu; Duncan H Mak; Eric LaCasse; Christine Jacob; Stephen J Morris; Jacques Jolivet; Michael Andreeff
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4741-6.
2009: Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Anthracycline dose intensification in acute myeloid leukemia.
The New England journal of medicine 2009;361(13):1249-59.
2009: Peter L Greenberg; Zhuoxin Sun; Kenneth B Miller; John M Bennett; Martin S Tallman; Gordon Dewald; Elisabeth Paietta; Richard van der Jagt; Jessie G. Houston; Mary L Thomas; David Cella; Jacob M Rowe
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).
Blood 2009;114(12):2393-400.
2009: Elizabeth A Richey; E Allison Lyons; Jonathan R Nebeker; Veena Shankaran; June M McKoy; Thanh Ha Luu; Narissa Nonzee; Steven Trifilio; Oliver Sartor; Al B Benson; Kenneth R Carson; Beatrice J Edwards; Douglas Gilchrist-Scott; Timothy M Kuzel; Dennis W Raisch; Martin S Tallman; Dennis P West; Steven Hirschfeld; Antonio J Grillo-Lopez; Charles L Bennett
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4398-405.
2009: Marc R Mansour; Maria L Sulis; Veronique Duke; Letizia Foroni; Sarah Jenkinson; Kenneth Koo; Christopher G Allen; Rosemary E Gale; Georgina Buck; Sue Richards; Elisabeth Paietta; Jacob M Rowe; Martin S Tallman; Anthony H Goldstone; Adolfo Ferrando; David C Linch
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4352-6.
2009: Jayesh Mehta; Jayesh Mehta; Olga Frankfurt; Jessica Altman; Andrew M Evens; Martin S Tallman; Leo Gordon; Stephanie Williams; Jane Winter; Jairam Krishnamurthy; Sara Duffey; Veerpal Singh; Richard Meagher; DL Grinblatt; L Kaminer; Seema Singhal
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation.
Leukemia & lymphoma 2009;50(9):1434-41.
2009: Omar Abdel-Wahab; Ann Mullally; Cyrus V Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross Levine
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Blood 2009;114(1):144-7.
2009: Andrew Lamb; Jorge Cortes; Dong-Wook Kim; Pedro Dorlhiac-Llacer; Ricardo Pasquini; John DiPersio; Martin C Müller; Jerald P Radich; H Jean Khoury; Nina Khoroshko; M Brigid Bradley-Garelik; Chao Zhu; Martin S Tallman
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Blood 2009;113(25):6322-9.
2009: David A Dorr; Rachel Burdon; Dennis P West; Jennifer Lagman; Christina Georgopoulos; Steven M. Belknap; June M McKoy; Benjamin Djulbegovic; Beatrice J Edwards; Sigmund A Weitzman; Simone Boyle; Martin S Tallman; Moshe Talpaz; Oliver Sartor; Charles L Bennett
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3850-5.
2009: Angela DeMichele; Robert Gray; Michelle Horn; Jinbo Chen; Richard Aplenc; William P Vaughan; Martin S Tallman
Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer.
Cancer research 2009;69(10):4184-91.
2009: Adele K Fielding; Jacob M Rowe; Susan M Richards; Georgina Buck; Anthony V Moorman; I Jill Durrant; David I Marks; Andrew K McMillan; Mark R Litzow; Hillard M Lazarus; Letizia Foroni; Gordon Dewald; Ian M Franklin; Selina M Luger; Elisabeth Paietta; Peter H Wiernik; Martin S Tallman; Anthony H Goldstone
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.
Blood 2009;113(19):4489-96.
2009: Jane N Winter; David J Inwards; Stewart Spies; Gregory Wiseman; David Patton; William Erwin; Alfred W Rademaker; Bing Bing Weitner; Stephanie F Williams; Martin S Tallman; Ivana Micallef; Jayesh Mehta; Seema Singhal; Andrew M Evens; Michael Zimmer; Arturo Molina; Christine White; Leo I Gordon
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(10):1653-9.
2009: Martin S Tallman
Myeloid disease.
Current opinion in hematology 2009;16(2):63.
2009: Eytan Stein; Brandon McMahon; Hau Kwaan; Jessica K Altman; Olga Frankfurt; Martin S Tallman
The coagulopathy of acute promyelocytic leukaemia revisited.
Best practice & research. Clinical haematology 2009;22(1):153-63.
2009: Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo Coco
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Blood 2009;113(9):1875-91.
2009: Anaadriana Zakarija; Hau C Kwaan; Joel L Moake; Nicholas Bandarenko; Dilip K Pandey; June M McKoy; Paul R Yarnold; Dennis W Raisch; Jeffrey L Winters; Thomas J Raife; John F Cursio; Thanh Ha Luu; Elizabeth A Richey; Matthew J Fisher; Thomas L Ortel; Martin S Tallman; X Long Zheng; Masanori Matsumoto; Yoshihiro Fujimura; Charles L Bennett
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).
Kidney international. Supplement 2009;(112):S20-4.
2009: V Singh; J Krishnamurthy; S Duffey; R Meagher; M Villa; J Monreal; Andrew M Evens; Olga Frankfurt; J Altman; Leo Gordon; Martin S Tallman; S Williams; Jane Winter; Seema Singhal; Jayesh Mehta
Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?
Bone marrow transplantation 2009;43(4):301-5.
2009: Cynthia E Dunbar; Martin S Tallman
'Ghostbusting' at blood.
Blood 2009;113(3):502-3.
2009: Martin S Tallman; Vikram Mathews; John F DiPersio
Role of hematopoietic stem cell transplantation in acute myelogenous leukemia and myelodysplastic syndrome.
Cancer treatment and research 2009;144():415-39.
2009: Jeffrey Crawford; James Armitage; Lodovico Balducci; Charles L Bennett; Douglas W Blayney; Spero R Cataland; David C Dale; George D Demetri; Harry P Erba; James Foran; Alison G Freifeld; Marti Goemann; Mark L Heaney; Sally Htoy; Susan Hudock; Dwight D Kloth; David J Kuter; Gary H Lyman; Laura Boehnke Michaud; Sarah C Miyata; Martin S Tallman; Saroj Vadhan-Raj; Peter Westervelt; Michael K Wong
Myeloid growth factors.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(1):64-83.
2009: Martin S Tallman
Treatment of elderly adults with acute promyelocytic leukemia: put the pedal to metal.
Leukemia & lymphoma 2009;50(1):12-3.
2008: Martin S Tallman
What is the role of arsenic in newly diagnosed APL?
Best practice & research. Clinical haematology 2008;21(4):659-66.
2008: Martin S Tallman
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Clinical advances in hematology & oncology : H&O 2008;6(11):3-5.
2008: Margaret R O'Donnell; Frederick R Appelbaum; Steven E Coutre; Lloyd E Damon; Harry P Erba; James Foran; Jeffrey Lancet; Lori J Maness; Guido Marcucci; Peter Maslak; Michael Millenson; Joseph O Moore; Farhad Ravandi; Friedrich Schuening; Paul Shami; B Douglas Smith; Richard M Stone; Martin S Tallman; Eunice S Wang; Frank L White
Acute myeloid leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(10):962-93.
2008: Peter L Greenberg; Eyal Attar; Minoo Battiwalla; John M Bennett; Clara D Bloomfield; Carlos M DeCastro; H Joachim Deeg; Harry P Erba; James M Foran; Guillermo Garcia-Manero; Steven D Gore; David Head; Lori J Maness; Michael Millenson; Stephen D Nimer; Margaret R O'Donnell; Hussain I Saba; Paul J Shami; Kathy Spiers; Richard M Stone; Martin S Tallman; Peter Westervelt
Myelodysplastic syndromes.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(9):902-26.
2008: David I Marks; Waleska S Pérez; Wensheng He; Mei-Jie Zhang; Michael Bishop; Brian J Bolwell; Christopher N Bredeson; Edward A Copelan; Robert Peter Gale; Vikas Gupta; gregory alan hale; Luis M Isola; Ann Jakubowski; Armand Keating; Thomas R Klumpp; Hillard M Lazarus; Jane L Liesveld; Richard T Maziarz; Philip L McCarthy; Mitchell Sabloff; Gary Schiller; Jorge Sierra; Martin S Tallman; Edmond WALLER; Peter H Wiernik; Daniel J Weisdorf
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.
Blood 2008;112(2):426-34.
2008: Martin S Tallman
The expanding role of arsenic in acute promyelocytic leukemia.
Seminars in hematology 2008;45(3 Suppl 2):S25-9.
2008: Martin S Tallman
Introduction: evolution of targeted and multifunctional agents for leukemias and lymphomas.
Seminars in hematology 2008;45(3 Suppl 2):S1.
2008: Blazej Dolniak; Efstratios Katsoulidis; Nathalie Carayol; Jessica K Altman; Amanda J Redig; Martin S Tallman; Takeshi Ueda; Rie Watanabe-Fukunaga; Rikiro Fukunaga; Leonidas C Platanias
Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
The Journal of biological chemistry 2008;283(18):12034-42.
2008: Martin S Tallman
Myeloid disease.
Current opinion in hematology 2008;15(2):81.
2008: Charles L Bennett; Samuel Michael Silver; Benjamin Djulbegovic; Athena T Samaras; C Anthony Blau; Kara J Gleason; Sara E Barnato; Kathleen M Elverman; D Mark Courtney; June M McKoy; Beatrice J Edwards; Cara C Tigue; Dennis W Raisch; Paul R Yarnold; David A Dorr; Timothy M Kuzel; Martin S Tallman; Steven M Trifilio; Dennis P West; Stephen Y Lai; Michael Henke
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
JAMA : the journal of the American Medical Association 2008;299(8):914-24.
2008: Anthony H Goldstone; Susan M Richards; Hillard M Lazarus; Martin S Tallman; Georgina Buck; Adele K Fielding; Alan K Burnett; rajesh Chopra; Peter H Wiernik; Letizia Foroni; Elisabeth Paietta; Mark R Litzow; David I Marks; Jill Durrant; Andrew McMillan; Ian M Franklin; Selina M Luger; Niculae Ciobanu; Jacob M Rowe
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
Blood 2008;111(4):1827-33.
2008: Richard F Schlenk; Marcelo C Pasquini; Waleska S Pérez; Mei-Jie Zhang; Jürgen Krauter; Joseph H Antin; Asad Bashey; Brian J Bolwell; Thomas Büchner; Jean-Yves Cahn; Mitchell S Cairo; Edward A Copelan; Corey Cutler; Hartmut Döhner; Robert Peter Gale; Osman Ilhan; Hillard M Lazarus; Jane L Liesveld; Mark R Litzow; David I Marks; Richard T Maziarz; Philip L McCarthy; Stephen D Nimer; Jorge Sierra; Martin S Tallman; Daniel J Weisdorf; Mary M Horowitz; Arnold Ganser
HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(2):187-96.
2008: Denise M Oliansky; Frederick Appelbaum; Peter A Cassileth; Armand Keating; Jamie Kerr; Yago Nieto; Susan Stewart; Richard M Stone; Martin S Tallman; Philip L McCarthy; Theresa Hahn
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(2):137-80.
2008: Andrew M Evens; Jane N Winter; Nanjiang Hou; Beverly P Nelson; Alfred Rademaker; David Patton; Seema Singhal; Olga Frankfurt; Martin S Tallman; Steven T Rosen; Jayesh Mehta; Leo I Gordon
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
British journal of haematology 2008;140(4):385-93.
2008: Jessica K Altman; Patrick Yoon; Efstratios Katsoulidis; Barbara Kroczynska; Antonella Sassano; Amanda J Redig; Heather Glaser; Alison Jordan; Martin S Tallman; Nissim Hay; Leonidas C Platanias
Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.
The Journal of biological chemistry 2008;283(4):1992-2001.
2008: Martin S Tallman; Jessica K Altman
Curative strategies in acute promyelocytic leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2008;():391-9.
2008: Martin S Tallman
Acute myeloid leukemia; decided victories, disappointments, and detente: an historical perspective.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2008;():390.
2007: Michelle A Elliott; Mark R Litzow; Louis Letendre; Robert C Wolf; Curtis A Hanson; Ayalew Tefferi; Martin S Tallman
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival.
Blood 2007;110(13):4172-4.
2007: Olga Frankfurt; Jonathan D Licht; Martin S Tallman
Molecular characterization of acute myeloid leukemia and its impact on treatment.
Current opinion in oncology 2007;19(6):635-49.
2007: Steven M Trifilio; Seema Singhal; S Williams; Olga Frankfurt; Leo Gordon; Andrew M Evens; Jane Winter; Martin S Tallman; Judy Pi; Jayesh Mehta
Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.
Bone marrow transplantation 2007;40(5):451-6.
2007: Cara C Tigue; June M McKoy; Andrew M Evens; Steven M Trifilio; Martin S Tallman; Charles L Bennett
Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project.
Bone marrow transplantation 2007;40(3):185-92.
2007: Martin S Tallman; Gordon W Dewald; Sharavi Gandham; Brent R Logan; Armand Keating; Hillard M Lazarus; Mark R Litzow; Jayesh Mehta; Tanya Pedersen; Waleska S Pérez; Jacob M Rowe; Meir Wetzler; Daniel J Weisdorf
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.
Blood 2007;110(1):409-17.
2007: Martin S Tallman; Syed A Abutalib; Jessica K Altman
The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia.
Seminars in thrombosis and hemostasis 2007;33(4):330-8.
2007: Andrew M Evens; Jeffrey Cilley; Taylor Ortiz; Mrinal Gounder; Nanjiang Hou; Alfred Rademaker; Sarah Miyata; Kara Catsaros; Connie Augustyniak; Charles L Bennett; Martin S Tallman; Daina Variakojis; Jane N Winter; Leo I Gordon
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
British journal of haematology 2007;137(6):545-52.
2007: Charles L Bennett; Jonathan R Nebeker; Paul R Yarnold; Cara C Tigue; David A Dorr; June M McKoy; Beatrice J Edwards; John F Hurdle; Dennis P West; Denys Lau ; Cara Angelotta; Sigmund A Weitzman; Steven M. Belknap; Benjamin Djulbegovic; Martin S Tallman; Timothy M Kuzel; Al B Benson; Andrew M Evens; Steven M Trifilio; D Mark Courtney; Dennis W Raisch
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Archives of internal medicine 2007;167(10):1041-9.
2007: Susan O'Brien; Ellin Berman; Kapil N Bhalla; Edward A Copelan; Marcel P Devetten; Peter D Emanuel; Harry P Erba; Peter L Greenberg; Joseph O Moore; Donna Przepiorka; Jerald P Radich; Russell J Schilder; Paul Shami; B Douglas Smith; David S Snyder; Robert J Soiffer; Martin S Tallman; Moshe Talpaz; Meir Wetzler
Chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(5):474-96.
2007: Antonella Sassano; Efstratios Katsoulidis; Giovanni Antico; Jessica K Altman; Amanda J Redig; Saverio Minucci; Martin S Tallman; Leonidas C Platanias
Suppressive effects of statins on acute promyelocytic leukemia cells.
Cancer research 2007;67(9):4524-32.
2007: Gail H Vance; Haesook T Kim; Gary A Hicks; Athena M Cherry; Rodney Higgins; Rachael L Hulshizer; Martin S Tallman; Hugo F Fernandez; Gordon W Dewald
Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900).
Leukemia research 2007;31(5):605-9.
2007: June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steven M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis Giles
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
Leukemia research 2007;31(5):599-604.
2007: Steven M Trifilio; Gennethel Pennick; Judy Pi; Jennifer Zook; Mary Golf; Kimberley Kaniecki; Seema Singhal; Stephanie Williams; Jane Winter; Martin S Tallman; Leo Gordon; Olga Frankfurt; Andrew M Evens; Jayesh Mehta
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.
Cancer 2007;109(8):1532-5.
2007: Anthony V Moorman; Christine J Harrison; Georgina A N Buck; Susan M Richards; Lorna M Secker-Walker; Mary Martineau; Gail H Vance; Athena M Cherry; Rodney R Higgins; Adele K Fielding; Letizia Foroni; Elisabeth Paietta; Martin S Tallman; Mark R Litzow; Peter H Wiernik; Jacob M Rowe; Anthony H Goldstone; Gordon W Dewald
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.
Blood 2007;109(8):3189-97.
2007: Steven M Trifilio; Charles L Bennett; Paul R Yarnold; June M McKoy; Jorge P Parada; Jayesh Mehta; G Chamilos; Frank J Palella; L Kennedy; K Mullane; Martin S Tallman; Andrew M Evens; Marc H Scheetz; W Blum; D P Kontoyiannis
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.
Bone marrow transplantation 2007;39(7):425-9.
2007: Andrew M Evens; J K Altman; Bharat B Mittal; N Hou; A Rademaker; D Patton; L Kaminer; S Williams; S Duffey; Daina Variakojis; S Singhal; Martin S Tallman; J Mehta; Jane N Winter; Leo I Gordon
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):679-88.
2007: Martin S Tallman
Treatment of relapsed or refractory acute promyelocytic leukemia.
Best practice & research. Clinical haematology 2007;20(1):57-65.
2007: Ian W Flinn; Donna Neuberg; Michael R Grever; Gordon W Dewald; john bennett; Elisabeth Paietta; Mohamad A Hussein; Frederick R Appelbaum; Richard A Larson; Dennis F Moore; Martin S Tallman
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):793-8.
2007: Michael R Grever; David M Lucas; Gordon W Dewald; Donna Neuberg; John C Reed; Shinichi Kitada; Ian W Flinn; Martin S Tallman; Frederick R Appelbaum; Richard A Larson; Elisabeth Paietta; Diane F Jelinek; John G Gribben; John C Byrd
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):799-804.
2007: Frederick R Appelbaum; Daniel Rosenblum; Robert J Arceci; William L Carroll; Philip P Breitfeld; Stephen J Forman; Richard A Larson; Stephanie J Lee; Sharon B Murphy; Susan O'Brien; Jerald P Radich; Nancy S Scher; Franklin O Smith; Richard M Stone; Martin S Tallman
End points to establish the efficacy of new agents in the treatment of acute leukemia.
Blood 2007;109(5):1810-6.
2007: Olga Frankfurt; Martin S Tallman
Growth factors in leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):203-15.
2007: Jeffrey Crawford; Betsy Althaus; James Armitage; Lodovico Balducci; Charles L Bennett; Douglas W Blayney; Spero R Cataland; David C Dale; George D Demetri; Harry P Erba; James Foran; Alison G Freifeld; Mark L Heaney; Sally Htoy; Dwight D Kloth; Gary H Lyman; Wells A Messersmith; Laura Boehnke Michaud; Sarah C Miyata; Amy Robbins; Martin S Tallman; Saroj Vadhan-Raj; Peter Westervelt; Michael K Wong
Myeloid growth factors. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):188-202.
2007: Adele K Fielding; Susan M Richards; rajesh Chopra; Hillard M Lazarus; Mark R Litzow; Georgina Buck; I Jill Durrant; Selina M Luger; David I Marks; Ian M Franklin; Andrew K McMillan; Martin S Tallman; Jacob M Rowe; Anthony H Goldstone
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
Blood 2007;109(3):944-50.
2007: Brian T Layden; Mathew Joseph; Martin S Tallman; Leonidas C Platanias
Acute lymphoblastic leukemia in a patient with chronic cyanoacrylate exposure.
Acta haematologica 2007;118(4):242-3.
2006: Charles L Bennett; Andrew M Evens; Leslie A Andritsos; Lakshmi Balasubramanian; Mark Mai; Matthew J Fisher; Timothy M Kuzel; Cara Angelotta; June M McKoy; Julie M Vose; Philip J Bierman; David J Kuter; Steven M Trifilio; Steven M Devine; Martin S Tallman
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
British journal of haematology 2006;135(5):642-50.
2006: Patrick Yoon; Nick Giafis; Jessica Smith; Heather Mears; Efstratios Katsoulidis; Antonella Sassano; Jessica Altman; Amanda J Redig; Martin S Tallman; Leonidas C Platanias
Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.
Molecular cancer therapeutics 2006;5(11):2815-23.
2006: Adi Gidron; Martin S Tallman
2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
Leukemia & lymphoma 2006;47(11):2301-7.
2006: Syed A Abutalib; Martin S Tallman
Monoclonal antibodies for the treatment of acute myeloid leukemia.
Current pharmaceutical biotechnology 2006;7(5):343-69.
2006: Adi Gidron; Martin S Tallman
Hairy cell leukemia: towards a curative strategy.
Hematology/oncology clinics of North America 2006;20(5):1153-62.
2006: Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
British journal of haematology 2006;135(2):165-73.
2006: Padma Kannan-Thulasiraman; Efstratios Katsoulidis; Martin S Tallman; J Simon C Arthur; Leonidas C Platanias
Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide.
The Journal of biological chemistry 2006;281(32):22446-52.
2006: Mark R Litzow; Sandra Lee; John M Bennett; Gordon W Dewald; Robert E Gallagher; Vibha Jain; Elisabeth Paietta; Janis Racevskis; Steven R Rousey; Joseph J Mazza; Martin S Tallman
A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
Haematologica 2006;91(8):1105-8.
2006: Hillard M Lazarus; Susan M Richards; rajesh Chopra; Mark R Litzow; Alan K Burnett; Peter H Wiernik; Ian M Franklin; Martin S Tallman; Lucy Cook; Georgina Buck; I Jill Durrant; Jacob M Rowe; Anthony H Goldstone
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
Blood 2006;108(2):465-72.
2006: Nick Giafis; Efstratios Katsoulidis; Antonella Sassano; Martin S Tallman; Linda S Higgins; Angel R Nebreda; Roger J Davis; Leonidas C Platanias
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.
Cancer research 2006;66(13):6763-71.
2006: Jayesh Mehta; Leo I Gordon; Martin S Tallman; Jane N Winter; Andrew M Evens; A O Evens; O Frankfurt; SF Williams; DL Grinblatt; L Kaminer; R Meagher; Seema Singhal
Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
Bone marrow transplantation 2006;38(2):95-100.
2006: Marilyn L Slovak; Holly Gundacker; C D Bloomfield; G Dewald; Frederick R Appelbaum; R A Larson; Martin S Tallman; john bennett; Derek L Stirewalt; Soheil Meshinchi; Cheryl L Willman; Yaddanapudi Ravindranath; Todd A Alonzo; A J Carroll; S C Raimondi; Nyla A Heerema
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies.
Leukemia 2006;20(7):1295-7.
2006: Larry D Cripe; Kevin Rader; Martin S Tallman; Michael S Gordon; Elisabeth Paietta; John Bennett; Donna Neuberg; Mark R Litzow; Timothy E O'brien; Jacob M Rowe
Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Leukemia research 2006;30(7):823-7.
2006: Steven M Trifilio; Leo Gordon; Seema Singhal; Martin S Tallman; Andrew M Evens; K Rashid; M Fishman; K Masino; Judy Pi; Jayesh Mehta
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
Bone marrow transplantation 2006;37(11):997-1001.
2006: Seema Singhal; Leo I Gordon; Martin S Tallman; Jane N Winter; Andrew M Evens; A O Evens; O Frankfurt; SF Williams; DL Grinblatt; L Kaminer; R Meagher; Jayesh Mehta
Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation.
Bone marrow transplantation 2006;37(6):553-7.
2006: Mujahid A Rizvi; Andrew M Evens; Martin S Tallman; Beverly P Nelson; Steven T Rosen
T-cell non-Hodgkin lymphoma.
Blood 2006;107(4):1255-64.
2006: Martin S Tallman; Waleska S Pérez; Hillard M Lazarus; Robert Peter Gale; Richard T Maziarz; Jacob M Rowe; David I Marks; Jean-Yves Cahn; Asad Bashey; Michael Bishop; Neal Christiansen; Stanley R Frankel; Juan J García; Osman Ilhan; Mary J Laughlin; Jane Liesveld; Charles Linker; Mark R Litzow; Selina Luger; Philip L McCarthy; Gustavo A Milone; Santiago Pavlovsky; Gordon L Phillips; James A Russell; Ruben A Saez; Gary Schiller; Jorge Sierra; Roy S Weiner; Axel R Zander; Mei-Jie Zhang; Armand Keating; Daniel J Weisdorf; Mary M Horowitz
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006;12(2):204-16.
2006: Yi-Hua Chen; Martin S Tallman; Charles L Goolsby; LoAnn Peterson
Immunophenotypic variations in hairy cell leukemia.
American journal of clinical pathology 2006;125(2):251-9.
2006: Martin S Tallman
Immune therapy in haematological malignancies.
Best practice & research. Clinical haematology 2006;19(4):635-6.
2006: Martin S Tallman
New agents for the treatment of acute myeloid leukemia.
Best practice & research. Clinical haematology 2006;19(2):311-20.
2006: Peter L Greenberg; Maria R Baer; John M Bennett; Clara D Bloomfield; Carlos M De Castro; H Joachim Deeg; Marcel P Devetten; Peter D Emanuel; Harry P Erba; Eli Estey; James Foran; Steven D Gore; Michael Millenson; Willlis H Navarro; Stephen D Nimer; Margaret R O'Donnell; Hussain I Saba; Kathy Spiers; Richard M Stone; Martin S Tallman
Myelodysplastic syndromes clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(1):58-77.
2006: Olga Frankfurt; Martin S Tallman
Strategies for the treatment of acute promyelocytic leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(1):37-50.
2006: Margaret R O'Donnell; Frederick R Appelbaum; Maria R Baer; John C Byrd; Steven E Coutre; Lloyd E Damon; Harry P Erba; Eli Estey; James Foran; Jeffrey Lancet; Lori J Maness; Peter Maslak; Michael Millenson; Joseph O Moore; Donna Przepiorka; Paul Shami; B Douglas Smith; Richard M Stone; Martin S Tallman
Acute myeloid leukemia clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(1):16-36.
2005: Jacob M Rowe; Georgina Buck; Alan K Burnett; rajesh Chopra; Peter H Wiernik; Susan M Richards; Hillard M Lazarus; Ian M Franklin; Mark R Litzow; Niculae Ciobanu; H Grant Prentice; Jill Durrant; Martin S Tallman; Anthony H Goldstone
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.
Blood 2005;106(12):3760-7.
2005: Charles L Bennett; Denis Cournoyer; Kenneth R Carson; Jérôme Rossert; stefano luminari; Andrew M Evens; Francesco Locatelli; Steven M. Belknap; June M McKoy; E Allison Lyons; Benjamin Kim; Rishi Sharma; Stacey Costello; Edwin B Toffelmire; George A Wells; Hans A Messner; Paul R Yarnold; Steven M Trifilio; Dennis W Raisch; Timothy M Kuzel; Allen R Nissenson; Lay-Cheng Lim; Martin S Tallman; Nicole Casadevall
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.
Blood 2005;106(10):3343-7.
2005: Susan O'Brien; Ellin Berman; Kapil N Bhalla; Edward A Copelan; Marcel P Devetten; Peter D Emanuel; Harry P Erba; Peter L Greenberg; Joseph O Moore; Donna Przepiorka; Jerald P Radich; Russell J Schilder; Paul Shami; B Douglas Smith; David S Snyder; Robert J Soiffer; Martin S Tallman; Moshe Talpaz; Meir Wetzler
Chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(6):732-55.
2005: Miguel A Sanz; Martin S Tallman; Francesco Lo Coco
Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia.
The oncologist 2005;10(10):806-14.
2005: Efstratios Katsoulidis; Yongzhong Li; Patrick Yoon; Antonella Sassano; Jessica Altman; Padma Kannan-Thulasiraman; Lakshmi Balasubramanian; Simrit Parmar; John Varga; Martin S Tallman; Amit Verma; Leonidas C Platanias
Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes.
Cancer research 2005;65(19):9029-37.
2005: M Tomblyn; Leo I Gordon; Seema Singhal; Martin S Tallman; S Williams; Jane N Winter; Andrew M Evens; Jayesh Mehta
Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF.
Bone marrow transplantation 2005;36(8):663-6.
2005: Simrit Parmar; Jessica Smith; Antonella Sassano; Shahab Uddin; Efstratios Katsoulidis; Beata Majchrzak; Suman Kambhampati; Elizabeth A Eklund; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
Blood 2005;106(7):2436-43.
2005: Martin S Tallman; D Gary Gilliland; Jacob M Rowe
Drug therapy for acute myeloid leukemia.
Blood 2005;106(4):1154-63.
2005: Punit Chadha; Alfred W Rademaker; Prateek Mendiratta; Benjamin Kim; Darren M Evanchuk; David Hakimian; LoAnn C Peterson; Martin S Tallman
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.
Blood 2005;106(1):241-6.
2005: Charles L Bennett; Jonathan R Nebeker; E Allison Lyons; Matthew H Samore; Marc D Feldman; June M McKoy; Kenneth R Carson; Steven M. Belknap; Steven M Trifilio; Glen T Schumock; Paul R Yarnold; Charles J Davidson; Andrew M Evens; Timothy M Kuzel; Jorge P Parada; Denis Cournoyer; Dennis P West; Oliver Sartor; Martin S Tallman; Dennis W Raisch
The Research on Adverse Drug Events and Reports (RADAR) project.
JAMA : the journal of the American Medical Association 2005;293(17):2131-40.
2005: Surinder Kaur; Simrit Parmar; Jessica Smith; Efstratios Katsoulidis; Yongzhong Li; Antonella Sassano; Beata Majchrzak; Shahab Uddin; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells.
Experimental hematology 2005;33(5):550-7.
2005: Miguel A Sanz; Martin S Tallman; Francesco Lo Coco
Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia.
Blood 2005;105(8):3019-25.
2005: Dan Douer; Martin S Tallman
Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2396-410.
2005: Martin S Tallman; Benjamin Brenner; Javier de la Serna; Hervé Dombret; Anna Falanga; Hau C Kwaan; Howard Liebman; Emmanuel Raffoux; Frederick R Rickles
Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom.
Leukemia research 2005;29(3):347-51.
2005: Arthur Zelent; Kevin Petrie; Zhu Chen; Reuben Lotan; Michael Lübbert; Martin S Tallman; Ryuzo Ohno; Laurent Degos; Samuel Waxman
Molecular target-based treatment of human cancer: summary of the 10th international conference on differentiation therapy.
Cancer research 2005;65(4):1117-23.
2005: Lakhvir Lal; Yongzhong Li; Jessica Smith; Antonella Sassano; Shahab Uddin; Simrit Parmar; Martin S Tallman; Saverio Minucci; Nissim Hay; Leonidas C Platanias
Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells.
Blood 2005;105(4):1669-77.
2005: Martin S Tallman; Anaadriana Zakarija
Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2005;32(1):99-103.
2005: A Gidron; Amit Verma; M Doyle; L Boggio; Andrew M Evens; Leo Gordon; Seema Singhal; Martin S Tallman; S Williams; Jane Winter; Jayesh Mehta
Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?
Bone marrow transplantation 2005;35(3):243-6.
2005: Martin S Tallman
New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2005;():143-50.
2005: Charles L Goolsby; Mary Paniagua; Martin S Tallman; Ronald B Gartenhaus
Bcl-2 regulatory pathway is functional in chronic lymphocytic leukemia.
Cytometry. Part B, Clinical cytometry 2005;63(1):36-46.
2005: Peter A Cassileth; Sandra J Lee; Mark R Litzow; Kenneth B Miller; Edward A Stadtmauer; Martin S Tallman; Hillard M Lazarus; John M Bennett; Elisabeth Paietta; Gordon W Dewald; Jacob M Rowe
Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995).
Leukemia & lymphoma 2005;46(1):55-61.
2005: Chadi Nabhan; Lynn M Rundhaugen; Mary Beth Riley; Alfred Rademaker; Larry Boehlke; Mashal Jatoi; Martin S Tallman
Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older.
Leukemia research 2005;29(1):53-7.
2004: Ronald L Sham; Martin S Tallman
Treatment of acute promyelocytic leukemia in the very elderly: case report and review of the literature.
Leukemia research 2004;28(12):1347-50.
2004: Chadi Nabhan; David Patton; Leo I Gordon; Mary Beth Riley; Timothy Kuzel; Martin S Tallman; Steven T Rosen
A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Leukemia & lymphoma 2004;45(11):2269-73.
2004: Peter H Wiernik; Elisabeth Paietta; Olga Goloubeva; S J Lee; D Makower; John M Bennett; James L Wade Iii; C Ghosh; L S Kaminer; J Pizzolo; Martin S Tallman
Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998).
Leukemia 2004;18(10):1605-10.
2004: Mary Eapen; Sergio Giralt; Mary M Horowitz; John P Klein; John E Wagner; Mei-Jie Zhang; Martin S Tallman; David I Marks; Bruce M Camitta; Richard E Champlin; Olle Ringdén; Christopher N Bredeson; R Martino; Robert Peter Gale; Mitchell S Cairo; Mark R Litzow; M deLima
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.
Bone marrow transplantation 2004;34(8):721-7.
2004: Martin S Tallman
Extramedullary acute myeloid leukemia infiltrates.
Leukemia research 2004;28(10):1005-6.
2004: Charles L Bennett; stefano luminari; Allen R Nissenson; Martin S Tallman; Stephen A Klinge; Norene McWilliams; June M McKoy; Benjamin Kim; E Allison Lyons; Steven M Trifilio; Dennis W Raisch; Andrew M Evens; Timothy M Kuzel; Glen T Schumock; Steven M. Belknap; Francesco Locatelli; Jérôme Rossert; Nicole Casadevall
Pure red-cell aplasia and epoetin therapy.
The New England journal of medicine 2004;351(14):1403-8.
2004: Simrit Parmar; Lynn M Rundhaugen; Larry Boehlke; MaryBeth Riley; Chadi Nabhan; Adekunle Raji; John L Frater; Martin S Tallman
Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
Leukemia research 2004;28(9):909-19.
2004: Andrew M Evens; Martin S Tallman; Ronald B Gartenhaus
The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.
Leukemia research 2004;28(9):891-900.
2004: Martin S Tallman; Phil Lefebvre; R M Baine; M Shoji; I Cohen; D Green; Hau C Kwaan; Elisabeth Paietta; Frederick R Rickles
Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.
Journal of thrombosis and haemostasis : JTH 2004;2(8):1341-50.
2004: Chadi Nabhan; Lynn M Rundhaugen; M Jatoi; Mary Beth Riley; Larry Boehlke; LoAnn C Peterson; Martin S Tallman
Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(8):1231-6.
2004: William R Friedenberg; Martin S Tallman; Isadore Brodsky; Elisabeth Paietta; Jacob M Rowe; Sandra Lee; Kendrith M Rowland; George W Schnetzer; John C Reed
Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group.
Leukemia research 2004;28(8):813-9.
2004: Elisabeth Paietta; Adolfo Ferrando; Donna Neuberg; John M Bennett; Janis Racevskis; Hillard Lazarus; Gordon Dewald; Jacob M Rowe; Peter H Wiernik; Martin S Tallman; A Thomas Look
Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias.
Blood 2004;104(2):558-60.
2004: Simrit Parmar; Efstratios Katsoulidis; Amit Verma; Yongzhong Li; Antonella Sassano; Lakhvir Lal; Beata Majchrzak; Farhad Ravandi; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
The Journal of biological chemistry 2004;279(24):25345-52.
2004: Martin S Tallman; Hau C Kwaan
Intravascular clotting activation and bleeding in patients with hematologic malignancies.
Reviews in clinical and experimental hematology 2004;8(1):E1.
2004: Elisabeth Paietta; Olga Goloubeva; Donna Neuberg; John M Bennett; Robert E Gallagher; Janis Racevskis; Gordon Dewald; Peter H Wiernik; Martin S Tallman
A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes.
Cytometry. Part B, Clinical cytometry 2004;59(1):1-9.
2004: Chadi Nabhan; Ronald B Gartenhaus; Martin S Tallman
Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
Leukemia research 2004;28(5):429-42.
2004: Martin S Tallman
Acute promyelocytic leukemia as a paradigm for targeted therapy.
Seminars in hematology 2004;41(2 Suppl 4):27-32.
2004: Francis Giles; Martin S Tallman; Guillermo Garcia-Manero; Jorge E Cortes; Deborah A Thomas; William G Wierda; Srdan Verstovsek; Marta Hamilton; Emma Barrett; Maher Albitar; Hagop M Kantarjian
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Cancer 2004;100(7):1449-58.
2004: Martin S Tallman; Haesook T Kim; Elisabeth Paietta; John M Bennett; Gordon Dewald; Peter A Cassileth; Peter H Wiernik; Jacob M Rowe
Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1276-86.
2004: Amit Verma; J Pedicano; Steven M Trifilio; Seema Singhal; Martin S Tallman; Jane Winter; S Williams; Leo Gordon; J Monreal; Jayesh Mehta
How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?
Bone marrow transplantation 2004;33(7):715-9.
2004: Peter L Greenberg; Sandra Lee; Ranjana Advani; Martin S Tallman; Branimir I Sikic; Louis Letendre; Kathleen Dugan; Bert L Lum; David L Chin; Gordon Dewald; Elisabeth Paietta; John M Bennett; Jacob M Rowe
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(6):1078-86.
2004: Jacob M Rowe; Donna Neuberg; William Friedenberg; John M Bennett; Elisabeth Paietta; Adel Z Makary; Jane L Liesveld; Camille N Abboud; Gordon Dewald; F Ann Hayes; Martin S Tallman; Peter H Wiernik
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.
Blood 2004;103(2):479-85.
2004: Martin S Tallman
Relevance of pathologic classifications and diagnosis of acute myeloid leukemia to clinical trials and clinical practice.
Cancer treatment and research 2004;121():45-67.
2004: Jeffrey Cilley; C Rihn; J Monreal; Leo I Gordon; Seema Singhal; Martin S Tallman; S Williams; Jane Winter; Jayesh Mehta
Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?
Bone marrow transplantation 2004;33(2):161-4.
2003: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles Alan Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo Coco; Rein Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4642-9.
2003: Athena M Cherry; Stephanie R Brockman; Sarah F Paternoster; Gary A Hicks; Donna Neuberg; Rodney R Higgins; john bennett; Peter L Greenberg; Kenneth Miller; Martin S Tallman; Jacob Rowe; Gordon W Dewald
Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study.
Leukemia research 2003;27(12):1085-90.
2003: Lisa A Ladewski; Steven M. Belknap; Jonathan R Nebeker; Oliver Sartor; E Allison Lyons; Timothy C Kuzel; Martin S Tallman; Dennis W Raisch; Amy R Auerbach; Glen T Schumock; Hau C Kwaan; Charles L Bennett
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(20):3859-66.
2003: Martin S Tallman
Current management and new approaches in the treatment of APL.
Clinical advances in hematology & oncology : H&O 2003;1(10):580-1.
2003: Martin S Tallman; Jacob M Rowe
Long-term follow-up and potential for cure in acute promyelocytic leukaemia.
Best practice & research. Clinical haematology 2003;16(3):535-43.
2003: Richard Larson; Martin S Tallman
Retinoic acid syndrome: manifestations, pathogenesis, and treatment.
Best practice & research. Clinical haematology 2003;16(3):453-61.
2003: Giuseppe Avvisati; Martin S Tallman
All-trans retinoic acid in acute promyelocytic leukaemia.
Best practice & research. Clinical haematology 2003;16(3):419-32.
2003: Suman Kambhampati; Yongzhong Li; Amit Verma; Antonella Sassano; Beata Majchrzak; Dilip K Deb; Simrit Parmar; Nick Giafis; Dhan V Kalvakolanu; Arshad Rahman; Shahab Uddin; Saverio Minucci; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Activation of protein kinase C delta by all-trans-retinoic acid.
The Journal of biological chemistry 2003;278(35):32544-51.
2003: Marcie R Tomblyn; Martin S Tallman
New developments in antibody therapy for acute myeloid leukemia.
Seminars in oncology 2003;30(4):502-8.
2003: Elisabeth Paietta; Donna Neuberg; John M Bennett; Gordon Dewald; Jacob M Rowe; Peter A Cassileth; Larry D Cripe; Martin S Tallman; Peter H Wiernik
Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials.
Leukemia 2003;17(8):1544-50.
2003: Simrit Parmar; Martin S Tallman
Acute promyelocytic leukaemia:a review.
Expert opinion on pharmacotherapy 2003;4(8):1379-92.
2003: Martin S Tallman; Robert Gray; Nicholas J Robert; Charles F LeMaistre; C Kent Osborne; William P Vaughan; William J Gradishar; Thomas M Pisansky; John H Fetting; Elisabeth Paietta; Hillard M Lazarus
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
The New England journal of medicine 2003;349(1):17-26.
2003: John L Frater; Martin S Tallman; Daina Variakojis; Brian J Druker; Debra Resta; Mary Beth Riley; Mary Ann Hrisinko; LoAnn C Peterson
Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
American journal of clinical pathology 2003;119(6):833-41.
2003: MY Ali; Yu Oyama; J Monreal; Jane N Winter; Martin S Tallman; SF Williams; Seema Singhal; Leo I Gordon; Jayesh Mehta
Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?
Bone marrow transplantation 2003;31(10):861-4.
2003: Robert E Gallagher; Beow Y Yeap; Wanli Bi; Kenneth J Livak; Nike Beaubier; Sreenivas Rao; Clara D Bloomfield; Frederick R Appelbaum; Martin S Tallman; James L Slack; Cheryl L Willman
Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.
Blood 2003;101(7):2521-8.
2003: Anaadriana Zakarija; LoAnn C Peterson; Martin S Tallman
Splenectomy and treatments of historical interest.
Best practice & research. Clinical haematology 2003;16(1):57-68.
2003: John L Frater; Nabeel R Yaseen; LoAnn C Peterson; Martin S Tallman; Charles L Goolsby
Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage.
Archives of pathology & laboratory medicine 2003;127(3):356-9.
2003: Bob Löwenberg; James D Griffin; Martin S Tallman
Acute myeloid leukemia and acute promyelocytic leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2003;():82-101.
2003: Martin S Tallman
Bleeding in acute leukemia.
Pathophysiology of haemostasis and thrombosis 2003;33 Suppl 1():48-9.
2003: Honorio T Benzon; Muhammad Iqbal; Martin S Tallman; Larry Boehlke; Eric J Russell
Superior sagittal sinus thrombosis in a patient with postdural puncture headache.
Regional anesthesia and pain medicine 2003;28(1):64-7.
2002: Martin S Tallman; Janet W Andersen; Charles Alan Schiffer; Frederick R Appelbaum; James Feusner; William G Woods; Angela Ogden; Howard Weinstein; Lois Shepherd; Cheryl Willman; Clara D Bloomfield; Jacob M Rowe; Peter H Wiernik
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
Blood 2002;100(13):4298-302.
2002: Martin S Tallman
Current treatment strategies for patients with hairy cell leukemia.
Reviews in clinical and experimental hematology 2002;6(4):389-400; discussion 449-50.
2002: MY Ali; Yu Oyama; J Monreal; Jane Winter; Martin S Tallman; Leo I Gordon; S Williams; Seema Singhal; Jayesh Mehta
Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 10(9)/l neutrophils on 3 consecutive days to define myeloid recovery.
Bone marrow transplantation 2002;30(11):749-52.
2002: Chadi Nabhan; L A Peterson; S A Kent; Martin S Tallman; G Dewald; Pratik Multani; Leo I Gordon
Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma.
Leukemia & lymphoma 2002;43(11):2145-9.
2002: A Lal; Martin S Tallman; M B Soble; I Golubovich; LoAnn Peterson
Hairy cell leukemia presenting as localized skeletal involvement.
Leukemia & lymphoma 2002;43(11):2207-11.
2002: Martin S Tallman
Monoclonal antibody therapies in leukemias.
Seminars in hematology 2002;39(4 Suppl 3):12-9.
2002: Martin S Tallman
Advancing the treatment of hematologic malignancies through the development of targeted interventions.
Seminars in hematology 2002;39(4 Suppl 3):1-5.
2002: M Tomblyn; L Gordon; Seema Singhal; Martin S Tallman; S Williams; Jane Winter; Jayesh Mehta
Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea.
Bone marrow transplantation 2002;30(8):517-9.
2002: Martin S Tallman; Chadi Nabhan
Management of acute promyelocytic leukemia.
Current oncology reports 2002;4(5):381-9.
2002: Mark A Weiss; Timothy B Aliff; Martin S Tallman; Stanley R Frankel; Matt Kalaycio; Peter Maslak; Joseph G Jurcic; David A Scheinberg; Todd E Roma
A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
Cancer 2002;95(3):581-7.
2002: D Gary Gilliland; Martin S Tallman
Focus on acute leukemias.
Cancer cell 2002;1(5):417-20.
2002: Vonda K Douglas; Martin S Tallman; Larry D Cripe; LoAnn C Peterson
Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders.
American journal of clinical pathology 2002;117(6):844-50.
2002: Hervé Dombret; Pierre Fenaux; Steven L Soignet; Martin S Tallman
Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy.
Seminars in hematology 2002;39(2 Suppl 1):8-13.
2002: Martin S Tallman
Introduction.
Seminars in hematology 2002;39(2 Suppl 1):1-2.
2002: Jayesh Mehta; Seema Singhal; L Gordon; Martin S Tallman; S Williams; Ronnie F Luyun; MY Ali; Yu Oyama; M Villa; T Shook; Jane Winter
Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells.
Bone marrow transplantation 2002;29(7):563-7.
2002: Martin S Tallman
Understanding the action of interferon in hairy cell leukemia: the past as prologue.
Leukemia research 2002;26(4):407-8.
2002: Chadi Nabhan; Martin S Tallman
Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia.
Clinical lymphoma 2002;2 Suppl 1():S19-23.
2002: Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; françois guilhot; Charles Alan Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian J Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole B Miller; Martin S Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
The New England journal of medicine 2002;346(9):645-52.
2002: Martin S Tallman
Retinoic acid syndrome: a problem of the past?
Leukemia 2002;16(2):160-1.
2002: Martin S Tallman; Chadi Nabhan; James Feusner; Jacob M Rowe
Acute promyelocytic leukemia: evolving therapeutic strategies.
Blood 2002;99(3):759-67.
2002: James L Slack; Samuel Waxman; Guido Tricot; Martin S Tallman; Clara D Bloomfield
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
The oncologist 2002;7 Suppl 1():1-13.
2001: Steven L Soignet; Stanley R Frankel; Dan Douer; Martin S Tallman; Andrew Lamb; Elizabeth Calleja; Richard M Stone; Matt Kalaycio; David A Scheinberg; Peter G Steinherz; E L Sievers; S Coutré; S Dahlberg; R Ellison; RP Warrell
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18):3852-60.
2001: Martin S Tallman
Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Blood reviews 2001;15(3):133-42.
2001: Jayesh Mehta; Yu Oyama; Jane Winter; S Williams; Martin S Tallman; Seema Singhal; M Villa; T Shook; R Burt; Ann Traynor; Gerald A Soff; S Masarik; G Ramsey; L Gordon
CD34(+) cell collection efficiency does not correlate with the pre-leukapheresis hematocrit.
Bone marrow transplantation 2001;28(6):597-601.
2001: C Nabhan; J Mehta; Martin S Tallman
The role of bone marrow transplantation in acute promyelocytic leukemia.
Bone marrow transplantation 2001;28(3):219-26.
2001: A R Kini; L A Peterson; Martin S Tallman; Mark W Lingen
Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid.
Blood 2001;97(12):3919-24.
2001: J Hounshell; C Tomori; R Newlin; K Knox; L Rundhaugen; Martin S Tallman; Charles L Bennett
Changes in finances, insurance, employment, and lifestyle among persons diagnosed with hairy cell leukemia.
The oncologist 2001;6(5):435-40.
2001: Martin S Tallman
Therapy of acute myeloid leukemia.
Cancer control : journal of the Moffitt Cancer Center 2001;8(1):62-78.
2000: Frederick R Appelbaum; Maria R Baer; M H Carabasi; Steven E Coutre; Harry P Erba; Eli Estey; MJ Glenn; E H Kraut; Peter Maslak; Michael Millenson; Carole B Miller; Hussain I Saba; R Stone; Martin S Tallman
NCCN Practice Guidelines for Acute Myelogenous Leukemia.
Oncology (Williston Park, N.Y.) 2000;14(11A):53-61.
2000: Ellin Berman; Reginald Clift; Edward A Copelan; Peter D Emanuel; Harry P Erba; MJ Glenn; Peter L Greenberg; Richard J Jones; S O'Brien; Hussain I Saba; Russell J Schilder; D S Snyder; Robert J Soiffer; Martin S Tallman; M Wetzler; F Ravandi-Kashani; Andrew Lamb; Moshe Talpaz
NCCN Practice Guidelines for Chronic Myelogenous Leukemia.
Oncology (Williston Park, N.Y.) 2000;14(11A):229-40.
2000: Martin S Tallman; Donna Neuberg; John M Bennett; C J Francois; Elisabeth Paietta; Peter H Wiernik; Gordon Dewald; Peter A Cassileth; Martin M Oken; Jacob M Rowe
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.
Blood 2000;96(7):2405-11.
2000: Michael S Gordon; ML Young; Martin S Tallman; Larry D Cripe; J M Bennett; Elisabeth Paietta; W Longo; H Gerad; J Mazza; Jacob M Rowe
Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.
Leukemia research 2000;24(10):871-5.
2000: Martin S Tallman; Philip Rowlings; Gustavo A Milone; Mei-Jie Zhang; Waleska S Perez; Daniel Weisdorf; Armand Keating; Robert Peter Gale; R B Geller; Mary J Laughlin; Hillard M Lazarus; S M Luger; Philip L McCarthy; J M Rowe; RA Saez; MR Vowels; Mary M Horowitz
Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission.
Blood 2000;96(4):1254-8.
2000: S Lee; Martin S Tallman; Martin M Oken; Peter A Cassileth; John M Bennett; Peter H Wiernik; Jacob M Rowe
Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group.
Leukemia 2000;14(8):1345-8.
2000: Charles L Bennett; Tammy Stinson; Joseph H Laver; Michael Bishop; J E Godwin; Martin S Tallman
Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making.
Leukemia & lymphoma 2000;37(1-2):65-70.
2000: James L Slack; Cheryl L Willman; J W Andersen; YP Li; David S Viswanatha; Clara D Bloomfield; Martin S Tallman; Robert E Gallagher
Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129.
Blood 2000;95(2):398-403.
2000: Martin S Tallman; Janet W Andersen; Charles Alan Schiffer; Frederick R Appelbaum; James Feusner; Angela Ogden; Lois Shepherd; Jacob M Rowe; C François; Richard Larson; Peter H Wiernik
Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.
Blood 2000;95(1):90-5.
1999: Charles L Bennett; Michael Bishop; Martin S Tallman; M R Somerfield; J Feinglass; Thomas J Smith
The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1355-9.
1999: R S Siegel; David Hakimian; W Spies; ER Wollins; LoAnn C Peterson; J Meyer; Martin S Tallman
Technetium-99m sulfur colloid scanning and correlative magnetic resonance imaging in patients with hairy cell leukemia and hypocellular bone marrow biopsies after 2-chlorodeoxyadenosine.
Leukemia & lymphoma 1999;35(1-2):171-7.
1999: Martin S Tallman; David Hakimian; Kenneth J Kopecky; S Wheaton; ER Wollins; K Foucar; Peter A Cassileth; Thomas M Habermann; Michael R Grever; Jacob M Rowe; LoAnn C Peterson
Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1665-70.
1999: M B Kleinman; Elizabeth Louise Wiley; M Guo; A W Rademaker; M Villa; Martin S Tallman; S B Newman; Leo I Gordon; Jane N Winter
Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy.
Bone marrow transplantation 1999;23(12):1297-301.
1999: Martin S Tallman; LoAnn C Peterson; David Hakimian; Shmuel Gillis; Aaron Polliack
Treatment of hairy-cell leukemia: current views.
Seminars in hematology 1999;36(2):155-63.
1999: Charles L Bennett; Tammy Stinson; Martin S Tallman; E A Stadtmauer; R W Marsh; W Friedenberg; H M Lazarus; L Kaminer; R M Golub; J M Rowe
Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(2):177-82.
1999: Ranjana Advani; Hussain I Saba; Martin S Tallman; Jacob M Rowe; P H Wiernik; J Ramek; Kathleen Dugan; Bert L Lum; J Villena; E Davis; Elisabeth Paietta; Litchman Manuel; Branimir I Sikic; Peter L Greenberg
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Blood 1999;93(3):787-95.
1999: Martin S Tallman; S Lee; Branimir I Sikic; Elisabeth Paietta; P H Wiernik; J M Bennett; J M Rowe
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Cancer 1999;85(2):358-67.
1999: Ranjana Advani; G Visani; Donald Milligan; Hussain I Saba; Martin S Tallman; Jacob M Rowe; P H Wiernik; J Ramek; Kathleen Dugan; Bert L Lum; J Villena; E Davis; Elisabeth Paietta; Litchman Manuel; A Covelli; Branimir I Sikic; P Greenberg
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
Advances in experimental medicine and biology 1999;457():47-56.
1999: Martin S Tallman
The thrombophilic state in acute promyelocytic leukemia.
Seminars in thrombosis and hemostasis 1999;25(2):209-15.
1998: Da-Cheng Zhou; Steven Hallam; S J Lee; Robert S Klein; Peter H Wiernik; Martin S Tallman; Robert E Gallagher
Constitutive expression of cellular retinoic acid binding protein II and lack of correlation with sensitivity to all-trans retinoic acid in acute promyelocytic leukemia cells.
Cancer research 1998;58(24):5770-6.
1998: William P Vaughan; Samuel Michael Silver; P G Beatty; Martin S Tallman
Roundtable discussion: Incorporating bone marrow transplantation into NCCN guidelines.
Oncology (Williston Park, N.Y.) 1998;12(11A):390-2.
1998: Martin S Tallman
Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond.
Leukemia 1998;12 Suppl 1():S37-40.
1998: Bruce D Cheson; JM Sorensen; Don Vena; MJ Montello; J A Barrett; Eugenio E Damasio; Martin S Tallman; Luciana Annino; J Connors; Bertrand Coiffier; F Lauria
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):3007-15.
1998: Wei Ding; YP Li; L M Nobile; G Grills; I Carrera; Elisabeth Paietta; Martin S Tallman; Peter H Wiernik; Robert E Gallagher
Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy.
Blood 1998;92(4):1172-83.
1998: Martin S Tallman; David Hakimian; L Peterson
Massive splenomegaly in hairy cell leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1232-3.
1998: L R Kong; C F Huang; David Hakimian; Daina Variakojis; L Klein; T M Kuzel; Leo I Gordon; C Zanzig; ER Wollins; Martin S Tallman
Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
Cancer 1998;82(5):957-64.
1998: Elisabeth Paietta; J Andersen; J Yunis; Jacob M Rowe; Peter A Cassileth; Martin S Tallman; John M Bennett; Peter H Wiernik
Acute myeloid leukaemia expressing the leucocyte integrin CD11b-a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Eastern Cooperative Oncology Group.
British journal of haematology 1998;100(2):265-72.
1998: Martin S Tallman; W J Gradishar
High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer.
Cancer chemotherapy and pharmacology 1998;42 Suppl():S60-7.
1997: John M Bennett; ML Young; J W Andersen; Peter A Cassileth; Martin S Tallman; Elisabeth Paietta; Peter H Wiernik; J M Rowe
Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience.
Cancer 1997;80(11 Suppl):2205-9.
1997: Martin S Tallman; A W Rademaker; L Jahnke; S G Brown; A Bauman; C Mangan; C Kelly; H Rubin; M S Kies; J Shaw; Krystyna Kiel; Leo I Gordon; W J Gradishar; Jane N Winter
High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer.
Bone marrow transplantation 1997;20(9):721-9.
1997: Martin S Tallman; Janet W Andersen; Charles Alan Schiffer; Frederick R Appelbaum; James Feusner; Angela Ogden; Lois Shepherd; C Willman; Clara D Bloomfield; Jacob M Rowe; Peter H Wiernik
All-trans-retinoic acid in acute promyelocytic leukemia.
The New England journal of medicine 1997;337(15):1021-8.
1997: J M Rowe; Martin S Tallman
Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged?
Blood 1997;90(6):2121-6.
1997: Robert E Gallagher; Cheryl L Willman; James L Slack; J W Andersen; YP Li; David S Viswanatha; Clara D Bloomfield; F R Appelbaum; Charles Alan Schiffer; Martin S Tallman; Peter H Wiernik
Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.
Blood 1997;90(4):1656-63.
1997: J Pandolfino; David Hakimian; Alfred W Rademaker; Martin S Tallman
Hypocholesterolemia in hairy cell leukemia: a marker for proliferative activity.
American journal of hematology 1997;55(3):129-33.
1997: YP Li; J Andersen; Arthur Zelent; S Rao; Elisabeth Paietta; Martin S Tallman; Peter H Wiernik; Robert E Gallagher
RAR alpha1/RAR alpha2-PML mRNA expression in acute promyelocytic leukemia cells: a molecular and laboratory-clinical correlative study.
Blood 1997;90(1):306-12.
1997: L R Kong; E Samuelson; Steven T Rosen; Henry H Roenigk; Martin S Tallman; A W Rademaker; Timothy M Kuzel
2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders.
Leukemia & lymphoma 1997;26(1-2):89-97.
1997: Charles L Bennett; R Golub; T M Waters; Martin S Tallman; J M Rowe
Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?
Cancer investigation 1997;15(3):227-36.
1997: Steven H Kroft; Martin S Tallman; J M Shaw; M Thangavelu; LoAnn C Peterson
Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA)
Leukemia 1997;11(1):170.
1996: W J Gradishar; Martin S Tallman; J S Abrams
High-dose chemotherapy for breast cancer.
Annals of internal medicine 1996;125(7):599-604.
1996: Martin S Tallman; David Hakimian; Alfred W Rademaker; C Zanzig; E Wollins; E Rose; LoAnn C Peterson
Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience.
Blood 1996;88(6):1954-9.
1996: Martin S Tallman
Differentiating therapy in acute myeloid leukemia.
Leukemia 1996;10(8):1262-8.
1996: Martin S Tallman
Differentiating therapy in acute myeloid leukemia.
Leukemia 1996;10 Suppl 2():s33-8.
1996: Martin S Tallman
Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia.
Leukemia 1996;10 Suppl 1():S12-5.
1996: William G Finn; M Thangavelu; K K Yelavarthi; Charles L Goolsby; Martin S Tallman; Ann Traynor; LoAnn C Peterson
Karyotype correlates with peripheral blood morphology and immunophenotype in chronic lymphocytic leukemia.
American journal of clinical pathology 1996;105(4):458-67.
1996: S Wheaton; Martin S Tallman; David Hakimian; L Peterson
Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Blood 1996;87(4):1556-60.
1996: Timothy M Kuzel; A Hurria; E Samuelson; Martin S Tallman; Henry H Roenigk; Alfred W Rademaker; Steven T Rosen
Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma.
Blood 1996;87(3):906-11.
1996: Martin S Tallman; David Hakimian
Current results and prospective trials of cladribine in chronic lymphocytic leukemia.
Seminars in hematology 1996;33(1 Suppl 1):23-7.
1996: Martin S Tallman
Deciphering the pathogenesis of coagulation dysfunction in leukemia.
Leukemia research 1996;20(1):13-6.
1996: Martin S Tallman
Good things come in small packages.
Cancer investigation 1996;14(2):182-3.
1996: J N Winter; H M Lazarus; A Rademaker; M Villa; C Mangan; Martin S Tallman; L Jahnke; L Gordon; S Newman; K Byrd; B W Cooper; N Horvath; E Crum; Edward A Stadtmauer; E Conklin; A Bauman; J Martin; Charles L Goolsby; S L Gerson; J Bender; Maurice O'Gorman
Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):277-86.
1995: A M Rosen; K Haines; Martin S Tallman; David Hakimian; R Ramsey-Goldman
Rapidly progressive cutaneous vasculitis in a patient with chronic myelomonocytic leukemia.
American journal of hematology 1995;50(4):310-2.
1995: Martin S Tallman; David Hakimian
Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders.
Blood 1995;86(7):2463-74.
1995: Robert E Gallagher; YP Li; S Rao; Elisabeth Paietta; J Andersen; PR Etkind; J M Bennett; Martin S Tallman; Peter H Wiernik
Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid.
Blood 1995;86(4):1540-7.
1995: Martin S Tallman; R Gray; J M Bennett; D Variakojis; N Robert; W C Wood; J M Rowe; P H Wiernik
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1557-63.
1995: Martin S Tallman; David Hakimian; C Zanzig; D K Hogan; A Rademaker; E Rose; Daina Variakojis
Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(4):983-8.
1995: Leo I Gordon; S G Brown; Martin S Tallman; A W Rademaker; S A Weitzman; H M Lazarus; C H Kelley; C Mangan; H Rubin; R M Fox
Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicity.
Free radical biology & medicine 1995;18(3):383-9.
1995: M D Volm; Martin S Tallman
Developments in the treatment of acute leukemia in adults.
Current opinion in oncology 1995;7(1):28-35.
1994: Martin S Tallman
All-trans-retinoic acid in acute promyelocytic leukemia and its potential in other hematologic malignancies.
Seminars in hematology 1994;31(4 Suppl 5):38-48.
1994: Martin S Tallman; J M Rowe
Acute promyelocytic leukemia: a paradigm for differentiation therapy with retinoic acid.
Blood reviews 1994;8(2):70-8.
1994: Mark Hoffman; Martin S Tallman; David Hakimian; D Janson; D Hogan; D Variakogis; Timothy M Kuzel; L I Gordon; Kanti Rai
2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):788-92.
1994: David Hakimian; Martin S Tallman; D K Hogan; Alfred W Rademaker; E Rose; A A Nemcek
Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(2):268-72.
1994: J N Winter; C Mangan; K Bryd; Martin S Tallman; L Gordon; L Jahnke; H Lazarus; B Cooper; E Crum; N Horvath
Combined therapy with rG-CSF and GM-CSF for the mobilization of hematopoietic progenitor cells.
Progress in clinical and biological research 1994;389():463-70.
1994: Martin S Tallman; David Hakimian; S Dyrda; C Kiley; A Nemcek; L Peterson
Assessment of complete remission after 2-chlorodeoxyadenosine for hairy cell leukemia: utility of marrow immunostaining and measurement of splenic index.
Leukemia & lymphoma 1994;14 Suppl 1():133-8.
1993: A A Ross; Brenda W Cooper; H M Lazarus; W Mackay; T J Moss; N Ciobanu; Martin S Tallman; M J Kennedy; Nancy E Davidson; D Sweet
Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques.
Blood 1993;82(9):2605-10.
1993: T M Kuzel; Martin S Tallman; D Shevrin; E Braud; L Kilton; P Johnson; J Kozlowski; N J Vogelzang; R Blough; Al B Benson
A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study.
Cancer 1993;72(6):1965-8.
1993: David Hakimian; Martin S Tallman; C Kiley; L Peterson
Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia.
Blood 1993;82(6):1798-802.
1993: Martin S Tallman; David Hakimian; H C Kwaan; F R Rickles
New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia.
Leukemia & lymphoma 1993;11(1-2):27-36.
1993: David Hakimian; Martin S Tallman; C Zugerman; W A Caro
Erythema nodosum associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia.
Leukemia 1993;7(5):758-9.
1993: Martin S Tallman; David Hakimian; J M Shaw; G S Lissner; E J Russell; Daina Variakojis
Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(4):690-7.
1993: Martin S Tallman; David Hakimian; D Snower; C M Rubin; H Reisel; D Variakojis
Basophilic differentiation in acute promyelocytic leukemia.
Leukemia 1993;7(4):521-6.
1992: Martin S Tallman; David Hakimian; Daina Variakojis; D Koslow; Gale Anne Sisney; Alfred W Rademaker; E Rose; K Kaul
A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia.
Blood 1992;80(9):2203-9.
1992: Martin S Tallman; P H Wiernik
Retinoids in cancer treatment.
Journal of clinical pharmacology 1992;32(10):868-88.
1992: Martin S Tallman; H C Kwaan
Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.
Blood 1992;79(3):543-53.
1991: Martin S Tallman; H C Kwaan; S A Weitzman
Detection of differentiation in acute promyelocytic leukemia.
Blood 1991;78(7):1892-3.
1991: C R Schad; W J Kraker; Syed M Jalal; Martin S Tallman; H N Londer; L P Cook; Robert B Jenkins
Use of fluorescent in situ hybridization for marker chromosome identification in congenital and neoplastic disorders.
American journal of clinical pathology 1991;96(2):203-10.
1991: S H McDunn; J N Winter; Daina Variakojis; Alfred W Rademaker; Jamie H Von Roenn; Martin S Tallman; Leo I Gordon; K D Bauer
Human immunodeficiency virus-related lymphomas: a possible association between tumor proliferation, lack of ploidy anomalies, and immune deficiency.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(8):1334-40.
1989: Martin S Tallman; Kenneth J Kopecky; D Amos; S Dahlberg; J S Hewlett; J C Files; C A Coltman; ED Thomas; Frederick R Appelbaum
Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(3):326-37.
1988: Timothy R McGuire; Martin S Tallman; G C Yee; John Nemunaitis; C S Higano; R W McGuffin; J W Singer
Influence of infusion duration on the efficacy and toxicity of intravenous cyclosporine in bone marrow transplant patients.
Transplantation proceedings 1988;20(3 Suppl 3):501-4.
1988: Martin S Tallman; John Nemunaitis; Timothy R McGuire; G C Yee; T E Hughes; J D Almgren; Frederick R Appelbaum; C S Higano; R W McGuffin; J W Singer
Comparison of two intravenous cyclosporine infusion schedules in marrow transplant recipients.
Transplantation 1988;45(4):810-3.
1987: Reginald Clift; C Dean Buckner; ED Thomas; Kenneth J Kopecky; Frederick R Appelbaum; Martin S Tallman; Rainer Storb; Jean Sanders; K Sullivan; M Banaji
The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation.
Bone marrow transplantation 1987;2(3):243-58.
1987: Martin S Tallman; Frederick R Appelbaum; D Amos; R S Goldberg; R B Livingston; J Mortimer; P L Weiden; ED Thomas
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(6):918-26.
1987: Martin S Tallman; R W McGuffin; C S Higano; G Starkebaum; S J Collins; H Johnston; J W Singer; D J Perry; A Kunath
Bone marrow transplantation in a patient with myelodysplasia associated with diffuse eosinophilic fasciitis.
American journal of hematology 1987;24(1):93-9.
1985: Martin S Tallman; M Levy
Hereditary sensory neuropathy with macular dystrophy.
Southern medical journal 1985;78(3):345-8.